« Return to News | Awards & Advancement

Standards Council of Canada recognizes PharmaNet lab

Wednesday, June 29, 2011 12:28 PM

PharmaNet Development Group, a provider of drug development services, said its bioanalytical laboratory in Quebec City, Canada, has received formal recognition from the Standards Council of Canada (SCC) for its compliance with the Organization for Economic Co-operation and Development (OECD) Principles of Good Laboratory Practice (GLP).

 "After an in-depth review by a four-person inspection team, the Standards Council of Canada awarded us with official recognition of GLP compliance," said Tony Jones, executive director, quality assurance and compliance.

"We have a long track record of successful inspections from global regulatory bodies, including a re-certification from Brazil's ANVISA just prior to the SCC inspection,” he said.

The final guidance describing the program was announced by Health Canada in April 2010. Thirty-four countries in North America, Europe and Asia constitute the OECD, an inter-governmental organization that pursues, among many other policies, the international harmonization of test methods and good laboratory practices. Upholding the principles of GLP ensures that a laboratory's quality system and management controls are consistent and reliable, which is essential for producing high-quality and valid test data.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.